Donna Judson, MD
Family Medicine · Cantonment, FLNPI 1447230479
Payments from drug & device makers
Across 245 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$619
- Lilly USA, LLC$484
- AstraZeneca$422
- Amgen$353
- Amarin Pharma, Inc.$266
- GSK$250
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,60399%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $619 |
| Lilly USA, LLC | 36 | $484 |
| AstraZeneca | 28 | $422 |
| Amgen | 19 | $353 |
| Amarin Pharma, Inc. | 17 | $266 |
| GSK | 23 | $250 |
| Teva Pharmaceuticals USA, Inc. | 12 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $169 |
| Pfizer | 6 | $135 |
| Avanir Pharmaceuticals, Inc. | 6 | $122 |
| Boehringer Ingelheim | 6 | $106 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Astellas Pharma US Inc | 4 | $78 |
| AbbVie(2 entities) | 2 | $35 |
| Novartis | 2 | $32 |
| Shire North American Group Inc | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Abbott | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Radius Health, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Organon | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$3,632 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $180,107 |
| MounjaroTirzepatide | 60 | $106,734 |
| EliquisApixaban | 60 | $82,038 |
| TrulicityDulaglutide | 44 | $67,455 |
| JardianceEmpagliflozin | 51 | $62,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $58,234 |
| JanuviaSitagliptin Phosphate | 22 | $30,774 |
| FarxigaDapagliflozin Propanediol | 23 | $25,784 |
| XareltoRivaroxaban | 28 | $23,070 |
| Bydureon BciseExenatide Microspheres | 11 | $21,814 |
| LinzessLinaclotide | 18 | $18,723 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $15,652 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,419 |
| RybelsusSemaglutide | 12 | $11,211 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $619 | $191,317170 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $484 | $176,343120 claims |
| PfizerEliquis | $135 | $82,03860 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $250 | $72,65477 claims |
| Boehringer IngelheimJardiance | $106 | $62,37951 claims |
| AstraZenecaFarxiga, Symbicort | $422 | $32,37749 claims |
| MerckJanuvia | $11 | $30,77422 claims |
| Johnson & JohnsonXarelto | $27 | $23,07028 claims |
| AbbVieLinzess | $35 | $18,72318 claims |
| Sanofi-aventis U.S. LLCLantus | $100 | $2,77415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Cantonment
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.